The spectrum of nephrocutaneous diseases and associations : Genetic causes of nephrocutaneous disease - 15/01/16
Abstract |
There are a significant number of diseases and treatment considerations of considerable importance relating to the skin and renal systems. This emphasizes the need for dermatologists in practice or in clinical training to be aware of these associations. Part I of this 2-part continuing medical education article reviews the genetic syndromes with both renal and cutaneous involvement that are most important for the dermatologist to be able to identify, manage, and appropriately refer to nephrology colleagues. Part II reviews the inflammatory syndromes with relevant renal manifestations and therapeutic agents commonly used by dermatologists that have drug-induced effects on or require close consideration of renal function. In addition, we will likewise review therapeutic agents commonly used by nephrologists that have drug-induced effects on the skin that dermatologists are likely to encounter in clinical practice. In both parts of this continuing medical education article, we discuss diagnosis, management, and appropriate referral to our nephrology colleagues in the context of each nephrocutaneous association. There are a significant number of dermatoses associated with renal abnormalities and disease, emphasizing the need for dermatologists to be keenly aware of their presence in order to avoid overlooking important skin conditions with potentially devastating renal complications. This review discusses important nephrocutaneous disease associations with recommendations for the appropriate urgency of referral to nephrology colleagues for diagnosis, surveillance, and early management of potential renal sequelae.
Le texte complet de cet article est disponible en PDF.Key words : autoimmune, dermatology, genetic, genodermatoses, inflammatory, nephrocutaneous, nephrology
Plan
Funding sources: None. |
|
Dr Menter has served on the advisory boards for Abbott, Amgen, Galderma, Janssen, and Wyeth, served as a consultant for Abbott, Amgen, Eli Lilly, Galderma, Janssen, LEO Pharma, Stiefel, and Wyeth, and served as an investigator for Abbott, Allergan, Amgen, Celgene, Eli Lilly, Janssen, Novartis, Novo Nordisk, Pfizer, Stiefel, Syntrix Biosystems, and Wyeth. He has also served as a speaker for Abbott, Amgen, Galderma, Janssen, LEO Pharma, and Wyeth, received grants from Abbott, Allergan, Amgen, Celgene, Eli Lilly, Janssen, Novartis, Novo Nordisk, Pfizer, Stiefel, and Syntrix Biosystems, and has received honoraria from Abbott, Amgen, Galderma, Janssen, LEO Pharma, Stiefel, and Wyeth. The other authors have no conflicts of interest to declare. |
|
Date of release: February 2016 |
|
Expiration date: February 2019 |
Vol 74 - N° 2
P. 231-244 - février 2016 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?